CAMBRIDGE, Mass.--(BUSINESS WIRE)--Glympse Bio, Inc. a life science company developing in vivo activity sensors to transform disease monitoring, today announced the appointment of Caroline J Loew, Ph.D., as President and Chief Executive Officer. As Chief Executive Officer, she will also serve on Glympse’s Board.
Dr. Loew joins Glympse from Bristol-Myers Squibb, where most recently she was Vice President, Head of R&D Strategy and Planning. At BMS she led portfolio strategy and operations in a role that included delivering strong competitive positioning for the portfolios in Immuno-Oncology, Immunoscience, Fibrosis and Cardiovascular, together with a fit-for-purpose operating model. Overall, she brings over 20 years of experience in senior roles at Bristol-Myers Squibb, Merck and PhRMA where she led teams in drug development and regulatory policy, market access and commercial. She earned her Ph.D. in Organic Chemistry and B.Sc. in Chemistry at Imperial College London.
“Caroline is an outstanding leader who brings a wealth of experience in life sciences, and we are thrilled she is joining Glympse. She is recognized for her acumen and operational execution, her ability to build talented teams and lead organizations, and for strategic development and commercialization of important products that change patients’ lives,” said Amy Schulman, Partner at LS Polaris Innovation Fund and Board member at Glympse. “We are also fortunate to have Sangeeta’s continuing scientific and clinical leadership on the Scientific Advisory Board.”
The addition of Dr. Loew brings seasoned strategic and operational leadership to the Company’s development programs, product engine and technology platform, and continues the Company’s emergence from stealth mode. Glympse first emerged from stealth in Summer 2018 with the announcements of a successful Series A financing of $22 million co-led by LS Polaris Innovation Fund and ARCH Ventures, as well as multiple research collaborations with pharmaceutical companies.
“I’m excited to join Glympse and work alongside the exceptional and dedicated team here,” said Dr. Loew. “Glympse’s powerful, tunable platform technology has the ability to transform how we detect and manage disease, and help both improve and save patients’ lives. I’m looking forward to building the company and fully realizing the potential of this platform for patients.”
Glympse Bio is transforming disease monitoring with a novel class of highly tunable and bioengineered activity sensors that query the body for disease status and report out clinically relevant insights rapidly and noninvasively. The company’s lead indication targets non-alcoholic steatohepatitis (NASH) - a growing pandemic that causes fibrosis and scarring of the liver – believed to afflict more than 100 million people worldwide and over 15 million in the United States alone. The Company’s development pipeline features programs in a variety of cancers, immune and infectious diseases.
Glympse’s co-founder, Sangeeta Bhatia, M.D. Ph.D., will lead the Scientific Advisory Board, in conjunction with her responsibilities as the Director of the Marble Center for Cancer Nanomedicine at MIT. The Company has also appointed Stanley Lapidus as Chairman, and Robert Langer Ph.D. to the Board of Directors, as it continues to strengthen its governance and leadership. Mr. Lapidus is an inventor and entrepreneur who has been founding CEO of four medical technology companies including Cytyc, EXACT Sciences, Helicos and SynapDx. Dr. Langer, one of only ten Institute Professors (the highest-ranking faculty position) at MIT, has more than 1,300 issued and pending patents, with his patents licensed or sublicensed to more than 350 pharmaceutical, chemical, biotechnology and medical device companies.
ABOUT GLYMPSE BIO, INC.
Glympse Bio is pioneering an in vivo sensing technology dedicated to transforming disease monitoring. The company has built a product engine enabling rapid development of tunable and bioengineered activity sensors for multiple indications including fibrosis, cancer, immunology and infectious diseases. The technology has been validated in 10 different diseases using multiple delivery methods and a broad range of analytical readouts. Glympse aims to improve healthcare globally by serving the needs of patients, clinicians, researchers, drug developers, and payors to help advance the science and our understanding of human diseases. The company is based at the Lab Central incubator in Cambridge, MA. For more information, please visit http://www.glympsebio.com.